DarioHealth Corp.

NASDAQ:DRIO

Medical - Diagnostics & Research

Healthcare
$5.13 -1.68%

-$0.12 today

Market cap
$50.27M
Beta
1.08
P/E (TTM)
5.5
EPS (TTM)
$1.26
52W Low $5.94High $17.74

Volume 0.01M

Average 0.01M

DRIO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

DarioHealth Corp.NASDAQ: DRIO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.44M fell 38.5% year over year, ahead of the -51.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 29.3% from the prior quarter. Over 3 fiscal years it compounded at -18.0% a year.

Context

  • Stock-based compensation amounted to 41.9% of revenue in FY2025, down 16.5 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -38.5% holds above the trailing-twelve-month pace of -51.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.44M-29.3% QoQ
Last fiscal yearDec 2025
$9.37M-40.7% YoY
LTMMar 2026
$5.51M-51.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.5%——
1 year-40.7%——
3-year CAGR-18.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.37M USD
Year-over-year change
-40.7%
4-year CAGR
-21.7%

Stock-Based Compensation vs competitors

How DRIO compares with its peers on the latest reported figures

  • DRIO's LTM Mar 2026 stock-based compensation of $5.51M is the 9th largest of the 11 companies compared; the peer median is $13.02M.
  • Its year-over-year change of -51.1% is the 8th highest of 10, against a peer median of -11.4%.
  • Stock-based compensation amounts to 26.0% of revenue for DRIO, versus a peer median of 5.6%.
DRIO Competitors Peer median
Stock-Based Compensation for DRIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OFIXOrthofix Medical Inc.LTM Mar 2026$42.3M +40.4%+15.9%5.1%
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M -7.4%-5.4%39.4%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$29.03M -33.3%+6.6%9.1%
ABSIAbsci CorporationLTM Mar 2026$13.53M -11.4%+13.5%737.0%
AVNSAvanos Medical, Inc.LTM Mar 2026$12.5M -10.7%-7.5%1.7%
VSTMVerastem, Inc.LTM Mar 2026$9.66M +26.4%+15.9%19.5%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$9.59M -84.2%-19.1%6.0%
DRIODarioHealth Corp.LTM Mar 2026$5.51M -51.1%-18.0%26.0%
INNVInnovAge Holding Corp.LTM Mar 2026$3.36M -56.6%+26.8%0.4%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$0 ——0.0%
Peer median (excluding DRIO) $13.02M-11.4%+6.6%5.6%

Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(76.76M)(62.19M)(59.43M)(42.75M)(41.71M)
Depreciation & Amortization4.46M4.72M4.99M7.43M2.83M
Deferred Income Tax00000
Stock-Based Compensation24.97M16.98M19.7M15.8M9.37M
Change in Working Capital(2.57M)(10.9M)4.07M(2.47M)2.21M
Accounts Receivables(367K)(5.11M)2.84M1.6M2.64M
Inventory(2.23M)(1.73M)2.89M308K437K
Accounts Payables1.08M(2.79M)(1.19M)(496K)(122K)
Other Working Capital(1.06M)(1.28M)(464K)(3.88M)(752K)
Other Non-Cash Items(503K)3.56M288K(16.57M)1.37M
Operating Cash Flow(50.41M)(47.85M)(30.38M)(38.56M)(25.94M)
Capital Expenditures(261K)(573K)(584K)(138K)(142K)
Acquisitions (Net)(7.47M)00(8.8M)0
Purchases of Investments00(5M)0(4.2M)
Sales of Investments005.03M00
Other Investing Activities(400K)(131K)000
Investing Cash Flow(8.13M)(573K)(547K)(8.93M)(4.34M)
Debt Repayment023.79M1.77M0185K
Common Stock Issued64.88M38.29M1.61M024.13M
Common Stock Repurchased0(134K)000
Dividends Paid00000
Other Financing Activities889K0000
Financing Cash Flow65.77M61.94M18.25M38.53M24.31M
Effect of Forex Changes000(68K)9K
Net Change in Cash7.22M13.52M(12.67M)(9.03M)(5.96M)
Free Cash Flow(50.67M)(48.42M)(30.96M)(38.7M)(26.08M)

DarioHealth Corp.

NASDAQ:DRIO

Intrinsic Alpha fair value

Locked

Current Price

$5.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.